Journal
MOLECULES
Volume 28, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/molecules28114473
Keywords
Benzoylaconitine; psoriasis; HaCaT keratinocytes; inflammatory cytokine; STAT3 signaling
Ask authors/readers for more resources
This study investigated the effects and mechanisms of Benzoylaconitine (BAC) on TNF-a/LPS-induced HaCaT keratinocytes in a IMQ-induced mice model of psoriasis. The results showed that BAC could alleviate psoriasis symptoms by inhibiting cell proliferation, inflammatory factors release, and Th17 cells accumulation. BAC also inhibited the phosphorylation of STAT3 and inflammatory cytokines levels in TNF-a/LPS-induced HaCaT keratinocytes. These findings suggest that BAC may be a potential therapeutic agent for psoriasis treatment in clinical practice.
Psoriasis is a chronic and multifactorial skin disease which is caused by inflammatory infiltrates, keratinocyte hyperproliferation, and accumulation of immune cells. As part of the Aconitum species, Benzoylaconitine (BAC) shows potential antiviral, anti-tumor, and anti-inflammatory effects. In this study, we investigated the effects and mechanisms of BAC on tumor necrosis factor-alpha (TNF-a)/LPS-induced HaCaT keratinocytes in a imiquimod(IMQ)-induced mice model. The results showed that BAC could relieve the symptoms of psoriasis by inhibiting cell proliferation, the release of inflammatory factors, and the accumulation of Th17 cells, while no obvious effect on cell viability and safety was observed both in vitro and in vivo. Additionally, BAC can markedly inhibit the protein and mRNA levels of inflammatory cytokines in TNF-a/LPS-induced HaCaT keratinocytes by inhibiting the phosphorylation of STAT3. In brief, our data indicated that BAC could alleviate the progression of psoriasis and may be a potential therapeutic agent for treating psoriasis in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available